Table 1.
Baseline characteristics of SLE patients with and without lupus pericarditis.
| All Patients (n = 689) |
With Pericarditis (n = 113) |
Without Pericarditis (n = 576) |
p-Value | ||||
|---|---|---|---|---|---|---|---|
| Age at admission, mean (SD) | 40.78 | 15.95 | 41.57 | 18.53 | 40.62 | 15.40 | 0.0165 * |
| Female, number (%) | 611 | 88.70 | 99 | 87.61 | 512 | 83.80 | 0.695 |
| Follow-up duration by year, mean (SD) | 7.31 | 5.11 | 6.44 | 5.48 | 7.55 | 5.02 | 0.048 * |
| Disease activity and serology, mean (SD) |
|||||||
| SLEDAI score | 12.92 | 6.34 | 16.75 | 7.25 | 12.17 | 5.87 | 0.0001 * |
| WBC count (μL) | 6304.85 | 3891.67 | 6683.19 | 3798.59 | 6230.63 | 3908.61 | 0.251 |
| Hemoglobin (mg/dL) | 11.30 | 5.30 | 10.17 | 2.36 | 11.53 | 5.68 | 0.013 * |
| PLT (k/μL) | 20.25 | 16.23 | 20.21 | 10.57 | 20.26 | 17.12 | 0.977 |
| Anti-dsDNA titer (WHO unit/mL) |
441.61 | 598.80 | 519.49 | 691.00 | 426.37 | 578.59 | 0.132 |
| C3 (mg/dL) | 63.38 | 32.85 | 60.85 | 32.28 | 69.84 | 32.78 | 0.008 * |
| C4 (mg/dL) | 13.59 | 9.59 | 12.38 | 8.39 | 13.83 | 9.79 | 0.142 |
| Comorbidity, number (%) | |||||||
| Diabetes | 50 | 7.3 | 6 | 5.3 | 44 | 7.7 | 0.383 |
| Hypertension | 220 | 31.9 | 44 | 40.0 | 176 | 30.6 | 0.201 |
| Cardiovascular event | 55 | 8.0 | 19 | 16.8 | 36 | 6.3 | 0.0001 * |
| End-stage renal disease | 66 | 9.6 | 19 | 16.8 | 47 | 8.2 | 0.004 * |
| Medication use, number (%) | |||||||
| Steroid | 677 | 98.3 | 111 | 98.2 | 566 | 98.2 | 0.98 |
| Hydroxychloroquine | 688 | 99.9 | 83 | 73.5 | 442 | 76.7 | 0.435 |
| Mycophenolic acid | 78 | 11.3 | 20 | 17.7 | 58 | 10.1 | 0.019 |
| Cyclophosphamide | 102 | 14.8 | 25 | 22.1 | 77 | 13.4 | 0.017 |
| Azathioprine | 268 | 38.9 | 52 | 46.0 | 216 | 37.5 | 0.092 |
SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index; WBC, white blood cell; Anti-dsDNA, anti-double strand DNA; C3, complement 3; C4, complement 4; SD, standard deviation; %, percentage; μL, microliter; dL, deciliter; mg, milligram; k, kilo; * p < 0.05.